Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BDX stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at BDX's multiple
Needs BDX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$42.31
Base
$61.15
Bull
$85.69
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
BDX vs JNJ
Medtronic plc
BDX vs MDT
DANAHER CORP /DE/
BDX vs DHR
STRYKER CORP
BDX vs SYK
REGENERON PHARMACEUTICALS, INC.
BDX vs REGN
BIOGEN INC.
BDX vs BIIB
VERTEX PHARMACEUTICALS INC / MA
BDX vs VRTX
Gilead Sciences, Inc.
BDX vs GILD
Moderna, Inc.
BDX vs MRNA
Eli Lilly and Company
BDX vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BDX can sustain revenue growth while improving margins and capital efficiency toward AMGN levels, then a selective buy is reasonable because the stock trades below its implied P/E value and near the lower end of its valuation ranges despite weaker current fundamentals.
BDX’s current price of $165.62 is 4.9% below the P/E-based implied price of $157.53, suggesting a small discount rather than a deep mispricing. The stock also sits within its historical band and close to the lower end of AMGN-implied range, but the valuation gap is tempered by BDX’s weaker profitability versus AMGN.
Supporting Metrics
